Magnetic nanoparticle design for medical diagnosis and therapy
暂无分享,去创建一个
[1] H. Honda,et al. Effective Solitary Hyperthermia Treatment of Malignant Glioma Using Stick Type CMC-magnetite. In vivo Study , 2004, Journal of Neuro-Oncology.
[2] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[3] Wolfgang Ebert,et al. Tissue-specific MR contrast agents. , 2003, European journal of radiology.
[4] M. Bellin,et al. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography , 2003, Abdominal Imaging.
[5] Sung-Wook Choi,et al. Surface Modification of Functional Nanoparticles for Controlled Drug Delivery , 2003 .
[6] P. Moroz,et al. Hepatic clearance of arterially infused ferromagnetic particles , 2003, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[7] J. Bulte,et al. Magnetoliposomes as contrast agents. , 2003, Methods in enzymology.
[8] P. Reimer,et al. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications , 2003, European Radiology.
[9] Timothy Ravasi,et al. The mononuclear phagocyte system revisited , 2002, Journal of leukocyte biology.
[10] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[11] P. Moroz,et al. Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model , 2002, Journal of surgical oncology.
[12] P. Moroz,et al. Arterial embolization hyperthermia in porcine renal tissue. , 2002, The Journal of surgical research.
[13] Rares Salomir,et al. Automatic control of hyperthermic therapy based on real‐time Fourier analysis of MR temperature maps , 2002, Magnetic resonance in medicine.
[14] T. S. St. Pierre,et al. Arterial embolization hyperthermia: hepatic iron particle distribution and its potential determination by magnetic resonance imaging. , 2002, Physics in medicine and biology.
[15] Nathan Kohler,et al. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. , 2002, Biomaterials.
[16] D D Allen,et al. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.
[17] P. Moroz,et al. Magnetically mediated hyperthermia: current status and future directions , 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[18] Y Rabin,et al. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? , 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[19] Jun Yoshida,et al. Targeting Hyperthermia for Renal Cell Carcinoma Using Human MN Antigenspecific Magnetoliposomes , 2001, Japanese journal of cancer research : Gann.
[20] A. Vekris,et al. Synthesis, magnetic properties, surface modification and cytotoxicity evaluation of Y3Fe5−xAlxO12 (0⩽x⩽2) garnet submicron particles for biomedical applications , 2001 .
[21] O. S. Nielsen,et al. A future for hyperthermia in cancer treatment? , 2001, European journal of cancer.
[22] P. Moroz,et al. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model , 2001, Journal of surgical oncology.
[23] P. Moroz,et al. Status of hyperthermia in the treatment of advanced liver cancer , 2001, Journal of Surgical Oncology.
[24] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[25] J. Kreuter,et al. Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.
[26] Peter Babinec,et al. SUPERPARAMAGNETIC GEL AS A NOVEL MATERIAL FOR ELECTROMAGNETICALLY INDUCED HYPERTHERMIA , 2001 .
[27] M. Cuyper,et al. Investigation of the spontaneous transferability of a phospholipid-poly(ethylene glycol)-biotin derivative from small unilamellar phospholipid vesicles to magnetoliposomes , 2001 .
[28] Jun Yoshida,et al. Preparation of Tumor-Specific Magnetoliposomes and Their Application for Hyperthermia , 2001 .
[29] A. V. Sergeev,et al. Evaluation of ferromagnetic fluids and suspensions for the site-specific radiofrequency-induced hyperthermia of MX11 sarcoma cells in vitro , 2001 .
[30] V. Mazokhin,et al. Technical aspects of electromagnetic hyperthermia in medicine. , 2001, Critical reviews in biomedical engineering.
[31] S. Loening,et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia , 2001 .
[32] P. Couvreur,et al. Design of folic acid-conjugated nanoparticles for drug targeting. , 2000, Journal of pharmaceutical sciences.
[33] S M Moghimi,et al. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.
[34] Robert E. Lenkinski,et al. Gadolinium-Loaded Nanoparticles: New Contrast Agents for Magnetic Resonance Imaging , 2000 .
[35] P. Couvreur,et al. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. , 2000, International journal of antimicrobial agents.
[36] R. Brooks,et al. Relaxometry and magnetometry of the MR contrast agent MION‐46L , 1999, Magnetic resonance in medicine.
[37] W. Kaiser,et al. Application of magnetite ferrofluids for hyperthermia , 1999 .
[38] P. Wust,et al. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles , 1999 .
[39] Okuhata,et al. Delivery of diagnostic agents for magnetic resonance imaging. , 1999, Advanced drug delivery reviews.
[40] J. Bulte,et al. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent , 1999 .
[41] Peter Wust,et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro , 1999 .
[42] R. Dorshow,et al. Polyethyleneglycol-stabilized manganese-substituted hydroxylapatite as a potential contrast agent for magnetic resonance imaging: particle stability in biologic fluids. , 1998, Investigative radiology.
[43] W. Kaiser,et al. Physical limits of hyperthermia using magnetite fine particles , 1998 .
[44] Moghimi,et al. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. , 1998, Advanced drug delivery reviews.
[45] J. Bacri,et al. Biomedical applications of maghemite ferrofluid. , 1998, Biochimie.
[46] K. Briley-Saebo,et al. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. , 1997, Magnetic resonance imaging.
[47] P Wust,et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. , 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[48] P Wust,et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[49] R Weissleder,et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. , 1996, AJNR. American journal of neuroradiology.
[50] M. Kamihira,et al. Preparation and characteristics of magnetite‐labelled antibody with the use of poly(ethylene glycol) derivatives , 1995, Biotechnology and applied biochemistry.
[51] P. Gasper,et al. Hyperthermic therapy for HIV infection. , 1995, Medical hypotheses.
[52] M. Shinkai,et al. Antibody‐conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia , 1995, Biotechnology and applied biochemistry.
[53] P. Jacobs,et al. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.
[54] C. W. Jung. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.
[55] G. A. Mercier. On the molecular spin density and the electrostatic potential as determinants of the relaxivity of metalloporphyrins. , 1995, Magnetic resonance imaging.
[56] K. Caldwell,et al. Surface Properties of Pluronic-Coated Polymeric Colloids , 1994 .
[57] R Weissleder,et al. MR lymphography: study of a high-efficiency lymphotrophic agent. , 1994, Radiology.
[58] R. Demeure,et al. Spin labelled arabinogalactan as MRI contrast agent. , 1994, Magnetic resonance imaging.
[59] G. Frija,et al. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. , 1994, AJR. American journal of roentgenology.
[60] P. Bunn,et al. Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer , 1993 .
[61] Ralph Weissleder,et al. Colloidal magnetic resonance contrast agents : effect of particle surface on biodistribution , 1993 .
[62] B. Scaife,et al. Relaxation and resonance in ferrofluids , 1993 .
[63] J. Bulte,et al. Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran‐magnetite particles , 1993, Magnetic resonance in medicine.
[64] S. Mann,et al. Magnetoferritin: in vitro synthesis of a novel magnetic protein. , 1992, Science.
[65] M. Bernardino,et al. Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. , 1992, Radiology.
[66] R. Brasch,et al. Rationale and applications for macromolecular Gd‐based contrast agents , 1991, Magnetic resonance in medicine.
[67] A. Fischman,et al. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging. , 1991, Radiology.
[68] P. C. Fannin. Measurement of the Neel relaxation of magnetic particles in the frequency range 1 kHz to 160 MHz , 1991 .
[69] R. Weissleder,et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.
[70] B. Künnecke,et al. Monoclonal antibody‐coated magnetite particles as contrast agents in magnetic resonance imaging of tumors , 1989, Magnetic resonance in medicine.
[71] R Weissleder,et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.
[72] B. Genetet,et al. A new immunoreagent for cell labeling. CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles. , 1988, Journal of immunological methods.
[73] M. Kumakura,et al. Polyacrolein microspheres as immunoreagents. , 1983, Journal of immunological methods.
[74] C. Gitler,et al. The selective detection of cell surface determinants by means of antibodies and acetylated avidin attached to highly fluorescent polymer microspheres. , 1983, Biochimica et biophysica acta.
[75] R. Gilchrist,et al. Selective Inductive Heating of Lymph Nodes , 1957, Annals of surgery.